Gilead Scores FDA Win for HDV Drug, CHMP Backs Trodelvy

Gilead Sciences (GILD) has secured FDA approval for Hepcludex (bulevirtide), making it the first therapy approved in the United States for chronic hepatitis delta virus (HDV) infection. In parallel, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Trodelvy (sacituzumab govitecan) for the treatment of triple-negative breast cancer (TNBC).

Hepcludex Approval Details

Hepcludex is a biologic drug that targets hepatocyte receptors to prevent HDV entry. It is administered as a weekly subcutaneous injection. The approval was based on clinical trial data showing significant reductions in viral DNA levels and improved liver function.

CHMP Recommendation for Trodelvy

The CHMP recommended Trodelvy for adult patients with advanced or metastatic TNBC who have received at least two prior systemic therapies. The final decision rests with the European Commission, which typically follows CHMP recommendations.

Company Stance

Gilead expressed commitment to delivering innovative treatments for liver diseases and cancer. The company confirmed that Hepcludex will be available soon in the U.S., while Trodelvy awaits the final European approval.

Potential Financial Impact

The approvals are expected to boost Gilead's revenue, particularly in the competitive hepatitis space. Pricing details have not been disclosed, but analysts anticipate a positive impact on the stock.